Pre-made Fidasimtamab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1;ERBB2/HER2 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-667

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-667 Category Tags ,

Product Details

Pre-Made Fidasimtamab biosimilar, Whole mAb, Anti-PDCD1/PD-1;ERBB2/HER2 Antibody: Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Fidasimtamab biosimilar, Whole mAb, Anti-PDCD1/PD-1;ERBB2/HER2 Antibody: Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody

INN Name

Fidasimtamab

Target

PDCD1,ERBB2

Format

Bispecific Whole mAb

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

G1;G1

VD LC

Kappa,Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None;1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD

99% SI Structure

None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC

95-98% SI Structure

None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6m

Year Proposed

2021

Companies

Hanmi Pharmaceutical,Innovent Biologics

Conditions Approved

NA

Conditions Active

Solid tumours

Conditions Discontinued

NA

Development Tech

Pentambody?

Previous Name

NA

Gm Offical Target Name

PDCD1,ERBB2

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide